This possibility could also explain the previous findings in HNSCC that the single inhibition of HER1 with cetuximab has an efficacy similar to the dual HER1/HER3 inhibition with duligotuzumab [58]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.